## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.5% in mid entry zone (3.0-6.0%), top quartile (81st pct) cross-sectional ranking. Short-term MRS_5 (2.5%) confirms momentum alignment. Strong momentum (+4.0% 5-day acceleration). Outperforming sector by 2.8%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($332.57)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. UnitedHealth stock ticks up after Barclays target hike as UNH earnings near**
- Source: ts2.tech | 20260105T170847 | Somewhat-Bullish | Relevance: 100%
- UnitedHealth shares saw an uptick after Barclays raised its price target and reiterated an "Overweight" rating, ahead of the company's full-year 2025 results and 2026 guidance release on January 27. Investors are focusing on medical-cost trends, especially the medical loss ratio, and the company's progress on operational review action plans amidst ongoing U.S. Justice Department investigations into its Medicare Advantage billing practices.

**2. Ariose Capital Management Ltd Makes New $1.38 Million Investment in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20260104T090846 | Somewhat-Bullish | Relevance: 100%
- Ariose Capital Management Ltd has made a new investment of $1.38 million in UnitedHealth Group Incorporated, purchasing 4,000 shares which now represent 0.5% of their portfolio. UnitedHealth Group (NYSE:UNH) slightly surpassed Q3 EPS expectations with revenues largely in line, maintaining a strong market presence and institutional ownership. The company offers a quarterly dividend of $2.21, and analyst ratings are mixed but generally lean towards a "Hold" with a target price around $385.54.

**3. TPG in talks to buy UnitedHealth's Optum UK unit, Sky News reports**
- Source: Reuters | 20260106T140829 | Somewhat-Bullish | Relevance: 100%
- U.S. private equity firm TPG is reportedly in talks to acquire UnitedHealth's Optum UK business for an estimated 1.2 billion to 1.4 billion pounds. The deal, which could be announced soon, would see Optum UK's electronic patient record systems for British general practitioners potentially combined with TPG's existing U.S.-based medical record software provider, Nextech. UnitedHealth had acquired the UK unit, EMIS, two years prior for 1.24 billion pounds.

**4. UnitedHealth Group Incorporated $UNH Position Boosted by Torray Investment Partners LLC**
- Source: MarketBeat | 20260106T120931 | Neutral | Relevance: 100%
- Torray Investment Partners LLC increased its stake in UnitedHealth Group (NYSE:UNH) by 15.7% in the third quarter, making the healthcare conglomerate its 12th largest holding. The company reported strong quarterly earnings, beating EPS estimates, and has a consensus "Hold" rating from analysts with mixed target adjustments ahead of its next earnings update. Several other institutional investors also adjusted their positions in UNH during recent quarters.

**5. UnitedHealth Group Incorporated $UNH Shares Sold by Commonwealth Equity Services LLC**
- Source: MarketBeat | 20260106T090931 | Somewhat-Bearish | Relevance: 100%
- Commonwealth Equity Services LLC reduced its stake in UnitedHealth Group by 13.5% in Q3 2025, selling over 42,000 shares. Despite this, other major institutions like Norges Bank and Berkshire Hathaway initiated significant positions, leading to a high institutional ownership. Analysts hold a "Hold" consensus rating with an average price target of $385.75, while the company faces near-term margin pressure ahead of its Q4 earnings and 2026 guidance announcement on January 27.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Barclays | $391 | $386 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 15 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +4.0% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.26 suggests fair value with growth premium. Forward P/E 19.7x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $316.1B |
| Beta | 0.42 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.26 |
| Forward P/E | 19.7 |
| Current P/E | 21.4 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.5% to 4.5% (+4.0% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 81st percentile. MRS_5 at 2.5% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.96), confirming momentum. OFD pattern: +DBH (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.50% (CS: 82) | Strong |
| RSI_14 | 64.9 | Neutral |
| MACD Histogram | 1.96 | Bullish |
| vs SMA20 | 1.051x | Above |
| vs SMA50 | 1.052x | Above |
| vs SMA200 | 1.007x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $349.25
- **Stop Loss:** $332.57 (4.8% risk)
- **Target:** $374.27 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 79
- **Position Value:** $27,590.75
- **Portfolio %:** 27.59%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*